

September Quarterly Shareholder update

Gary Phillips, CEO 30th October 2024

Forward looking statement

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forwardlooking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and

involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline terms, in a timely fashion or at we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.





Investment Highlights



Australian-founded clinical stage drug developer.



Backed by specialist healthcare investors – 54% institutional.



Focus on first-in-class and best-in-class drugs backed by in house long-life patent portfolio.



Funded to mid-2025 with near term data to drive value over 12-18 months.



Multiple shots on goal from additional Phase 2, Phase 1 and preclinical assets.



Experienced team with **proven track record** in licensing deals – \$100m raised.



Three Phase 2 studies in **blood cancer indications** with addressable market value >\$4.5 bn.



\$8.5m in non-dilutive grant funding awarded in last 3 years.



September Quarter Highlights

- Phase 2 blood cancer trial recruitment target achieved as 15th patient dosed with 12 patients exceeding one month treatment we plan to release interim results in December 2024
- Researchers at Heidelberg University to take SNT-5505 into the clinic for the blood cancers myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with A\$2.5m funding from Deutsche Krebshilfe (German Cancer Aid)
- Tim Luscombe appointed Chief Financial Officer
- \$5 million raised to provide essential funding for the Company's Phase 2 clinical trials



Shareholders & cash

Financial Information (ASX: SNT) Share price – 29 October 2024 \$0.044 Market Cap A\$60.42m Proforma cash balance (30 June 2024)¹ A\$10.4m Enterprise value A\$50.02m

Note:

1. Proforma cash of \$13.0m includes: cash (\$4.34m); 2024 R&D tax credit (\$4.56m); return of security deposit (\$0.9m), \$0.6 million of proceeds from the sale of the MBU.

Institutional Ownership	30 June 24
D&A Income Limited	20%
Platinum Investment Management Limited	15%
BVF Partners LP	9%
Total Institutional Ownership	54%

Share Price & Volume - YTD




^{*22} January volume 78.66m — crossing of stock between institutions after closure of fund



Syntara is the global leader in lysyl oxidase chemistry and biology

Multi year research program leveraged with extensive scientific collaborations worldwide has delivered three drugs now in phase 1c/2 studies

Lysyl oxidases mediate the final stage in fibrosis



Lysyl oxidase inhibition provides a true anti-fibrotic therapy, directly addressing the tissue stiffening that occurs due to increases in collagen and number of cross-links.

SNT-5505 in Oncology

- Clinical PoC: reduction of bone marrow collagen fibrosis grade in 45% of evaluable myelofibrosis patients in 6month Phase 2 study
- Excellent clinical safety and tolerability with a complementary mode of action to current standard of care
- INDs approved for myelofibrosis and hepatocellular carcinoma
- Potential in haematological indications such as MDS as well as solid tumours; two Nature publications
- Patent priority date of 2018 provides extended IP coverage

Topical pan-LOX inhibitors in Skin Scarring

- Clinical PoC: significant reduction of collagen and good safety in 3-month placebocontrolled Phase 1c study in patients with established scars
- Lead and back up compounds to support studies in multiple scar types (prevention of scar formation and modification of existing scars) in topical and oral dosage form
- Strong preclinical evidence in models of skin fibrosis and scarring; Nature publication
- Patent priority date of 2019 provides extended IP coverage




Myelofibrosis

A rare type of bone marrow cancer that disrupts the body's normal production of blood cells

Key Facts

- Affects ~15 in 1m people worldwide
- Age of onset typically from age 50; 5 years median survival
- 11% transformation to leukemia
- Reduced red blood cells can cause extreme tiredness (fatigue) or shortness of breath
- Reduced white blood cells can lead to an increased number of infections
- Reduced platelets can promote bleeding and/or bruising
- Spleen increases blood cell production and becomesenlarged
- Other common symptoms include fever, night sweats, and bone pain.

Primary Myelofibrosis is characterised by a build up of scar tissue (fibrosis) in bone marrow reducing the production of blood cells.



Current standard of care (SoC): JAK inhibition

- Symptomatic relief plus some limited survival improvement.
- 75% discontinuation at 5 years
- Median overall survival is 14 – 16 months after discontinuation

Commercial Opportunity

- Current SoC; revenue ~US\$1b per annum
- Recent history of biotech exits in excess of US\$1.7b

SNT-5505

In contrast to SoC SNT-5505 intervenes at the source, clearing fibrosis from the bone marrow and enabling the production of healthy blood cells to resume

Clinical positioning

- Distinct mode of action, improved tolerability and a profile suitable for combination with SoC
- In addition to symptomatic relief, potential for disease modification.



SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures

Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity

Study Design	Endpoints	Trial Outlooks
 IND approved Q3 2020 Open label Phase 2a 200mg BD dose (>90% inhibition of LOX enzyme) 21 trial sites in Australia, South Korea, Taiwan and USA Recruited 24 patients who were non responsive or inappropriate for JAKi treatment 13 patients completed 24 weeks of treatment 	 SNT-5505 has been well tolerated Majority of AEs were mild and not related to treatment 11 patients dropped out of the study, none due to treatment related AEs 	 5/11 evaluable patients had improved bone marrow fibrosis scores of ≥1 grade 5/13 had an improvement in symptom score of >20% 9/13 had stable/improved hemoglobin (Hb) counts 10/13 had stable/improved platelet counts No spleen volume response (SVR35) was identified



Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor

Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure

Design	Treatment Cohort	Endpoints
FDA reviewed interim monotherapy data and combination therapy protocol Q3 2023 Open label Phase 2a 52 week treatment period 15 patients SNT-5505 200mg BID + stable dose of RUX	Int-2/high risk PMF or post-ET/PV MF Treated with RUX ≥12 weeks (stable dose for ≥8 weeks) and not achieved complete remission per IWG criteria Population enriched with patients who reach predetermined thresholds in bone marrow fibrosis and symptom score	PRIMARY Safety SECONDARY PK/PD BMF Grade IWG Response SVR Hematology Symptom score Platelet response RUX dose modifications

ClinicalTrials.gov ID NCT04676529

*JAKi – Janus Kinase inhibitor, RUX – Ruxolitinib, MF myelofibrosis, ET Essential Thrombocythaemia, PV polycythaemia vera, INT intermediate, BMF bone marrow fibrosis,

PK pharmacokinetics, PD pharmacodynamics, SVR spleen volume response, IWG International Working Group Myeloproliferative Neoplasms

Safety Monitoring Committee (SMC) – 30 May 2024

- SMC consists of all Study Investigators, CRO Medical Monitor and Sponsor representative.
- 10 patients reviewed, 5/10 at 3 months
- Unanimous agreement from all voting members to continue the study

Study Plan

- 19 clinical trial sites
- Recruitment started 13 Dec 2023
- Fully recruited (August 2024)
- Interim 6 months data targeted for Dec 2024 at American Society of Hematology
- Top line data expected mid 2025

Interim data to drive FDA discussion on pivotal study design ← and potential partnering interest



Strong interest in myelofibrosis assets from strategics

Target / Acquiror











Date of Announcement	Feb-2024	June-2023	July-2022
Drug Name	Pelabresib	Pacritinib	Momelotinib
Lead Indication / Phase (at transaction)	Myelofibrosis (Successful Phase 3 studies)	Myelofibrosis (Marketed)	Myelofibrosis (FDA Filed – June)
Deal Type	Acquisition	Acquisition	Acquisition
Upfront / Milestones (USD)	US\$2.9B	US\$1.7B	US\$1.9B
Earnout Payments / Royalty Rate (%)	Subject to regulatory approvals	None	None



Potential to deliver near term value

Pipeline creates multiple opportunities in high value markets

Drug Candidate	Indication	Phase	Anticipated Upcoming Milestones	Addressable market (US\$)
SNT-5505	Myelofibrosis	Phase 2	Interim 6 month data December 2024	~\$1 billion ¹
	Myelodysplastic Syndrome Low & intermediate Risk + High risk trials	Phase 1c/2	Low/Int Risk Data H2 25 High Risk – Grant Pending	~\$3.2 billion ²
Oral and Topical Pan-LOX inhibitors	Scar prevention	Phase 2	Data H2 2025	~\$3.5 billion ³
	Modification of scarring process	Phase 1c	Pilot study in keloid scars planned	~\$3.5 billion ⁴
SNT-4728	IRBD and Parkinson's Disease	Phase 2	Data H2 2025	~\$3.5 billion⁵

MF: Addressable market, The Myelofibrosis market size across the 8MM was valued at \$2.39 billion in 2021: https://www.globaldata.com/store/report/myelofibrosis-market-analysis/

MDS: Addressable market, MYELODYSPLASTIC SYNDROME TREATMENT MARKET ANALYSIS, https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775 Scar Prevention: Global Scar Market 2020 page 40 and 71; Total scar treatment market in 2019 exceeded US\$19b. Keloid and hypertrophic scar segment ~US\$3.5b

Scar modification: Addressable market, Global Scar Market 2020 page 40 and 71. Total scar treatment market in 2019 exceeded US\$19b. Keloid and hypertrophic scar segment ~US\$3.5b

IRBD / Parkinson's Addressable market, Parkinson's Disease market size across the 7MM was valued at \$3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. https://www.globaldata.com/store/report/parkinsons-disease-major-market-analysis/



Recent & anticipated news flow

Strong and growing pipeline with advancement in studies expected to provide value inflection points

COMPLETED Q4 2023

SNT-4728 iRBD / neuro inflammation study commenced recruitment (8 November 2023) COMPLETED Q4 2023

SNT-5505 Phase 2a myelofibrosis study (monotherapy) completed and reports safety and efficacy data at ASH (10 December 2023) COMPLETED Q4 2023

SNT-5505 Phase 2a myelofibrosis combination study (add on to JAK inhibitor) commenced recruitment (12 December 2023) COMPLETED Q3 2024

SNT-5505 Phase 2a myelofibrosis combination study (add on to JAK inhibitor) completes recruitment Q4 2024

Syntara skin scarring clinical development plan to be announced

Q1 2025

SNT-5505 Phase 1c/2a low/int risk myelodysplastic syndrome study expected to commence recruitment Dec 2024

SNT-5505 Phase 2a myelofibrosis combination study (add on to JAK inhibitor) interim data with 6 months treatment to report safety and efficacy data target ASH Q4 2024

SNT-5505 Phase 2a myelofibrosis monotherapy study publication Q4 2024

SNT-4728 iRBD / neuro inflammation study recruitment update Q4 2024

Pan-LOX scar prevention for burn injuries- clinical trial to commence recruitment

B SYNT/A

Syntara Limited ABN 75 082 811 630



Gary Phillips

Chief Executive Officer gary.phillips@syntaraTX.com.au

